Publications by authors named "Simon Hume"
Background And Aims: Accurate biomarkers to predict outcomes following discontinuation of nucleos(t)ide analogue (NA) therapy are needed. We evaluated serum hepatitis B core-related antigen (HBcrAg) level as a biomarker for predicting outcomes after NA discontinuation.
Methods: Patients with HBeAg-negative chronic hepatitis B (CHB) without cirrhosis were enrolled in a prospective trial evaluating clinical outcomes until 96 weeks after NA discontinuation.
Background And Aims: HBV RNA in peripheral blood reflects HBV cccDNA transcriptional activity and may predict clinical outcomes. The prospective Melbourne HBV-STOP trial studied nucleot(s)ide analog discontinuation in HBeAg-negative non-cirrhotic participants with long-term virological suppression. Ninety-six weeks after stopping treatment, the proportion of participants with virological relapse (HBV DNA > 2000 IU/mL), biochemical relapse (ALT > 2 × ULN and HBV DNA > 2000 IU/mL), or hepatitis flare (ALT > 5 × ULN and HBV DNA > 2000 IU/mL) was 89%, 58%, and 38%, respectively.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the natural history of strictures in Crohn's disease, focusing on their inflammation and the effects of drug therapy using magnetic resonance enterography (MRE).
- Out of 136 patients with strictures, nearly half (46%) required surgery after 6 months, and specific MRE characteristics (like bowel dilatation and stricture thickness) were strong predictors for the need for surgery.
- Anti-TNF therapy was linked to a reduced risk of surgical intervention, suggesting that MRE can effectively guide treatment decisions and predict future patient outcomes.